{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T11:29:49Z","timestamp":1764588589379,"version":"3.40.5"},"reference-count":27,"publisher":"Termedia Sp. z.o.o.","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Med Sci"],"published-print":{"date-parts":[[2024,8,4]]},"DOI":"10.5114\/aoms\/176943","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T06:14:31Z","timestamp":1726726471000},"page":"1063-1068","source":"Crossref","is-referenced-by-count":1,"title":["Diarrhea-predominant irritable bowel syndrome as a masquerade for systemic mastocytosis: review article and illustrating case report"],"prefix":"10.5114","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6198-4574","authenticated-orcid":true,"given":"Mansour","family":"Aljabry","sequence":"first","affiliation":[{"name":"Pathology Department, College of Medicine, King Saud University, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3061","published-online":{"date-parts":[[2024,4,25]]},"reference":[{"key":"ref-1169188","doi-asserted-by":"crossref","unstructured":"Pardanani A. Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management. Am J Hematol 2023; 98: 1097-116.","DOI":"10.1002\/ajh.26962"},{"key":"ref-1169189","doi-asserted-by":"crossref","unstructured":"Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127: 2391-405.","DOI":"10.1182\/blood-2016-03-643544"},{"key":"ref-1169190","doi-asserted-by":"crossref","unstructured":"Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia 2022; 36: 1703-19.","DOI":"10.1038\/s41375-022-01613-1"},{"key":"ref-1169191","doi-asserted-by":"crossref","unstructured":"Guilarte M, Santos J, De Torres I, et al. Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut 2007; 56: 203-9.","DOI":"10.1136\/gut.2006.100594"},{"key":"ref-1169192","doi-asserted-by":"crossref","unstructured":"Pardanani A. Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management. Am J Hematol 2021; 96: 508-25.","DOI":"10.1002\/ajh.26118"},{"key":"ref-1169193","doi-asserted-by":"crossref","unstructured":"Scherber RM, Borate U. How we diagnose and treat systemic mastocytosis in adults. Br J Haematol 2018; 180: 11-23.","DOI":"10.1111\/bjh.14967"},{"key":"ref-1169194","doi-asserted-by":"crossref","unstructured":"Cruse G, Metcalfe DD, Olivera A. Functional deregulation of KIT: link to mast cell proliferative diseases and other neoplasms. Immunol Allergy Clin 2014; 34: 219-37.","DOI":"10.1016\/j.iac.2014.01.002"},{"key":"ref-1169195","doi-asserted-by":"crossref","unstructured":"Hauswirth AW, Simonitsch-Klupp I, Uffmann M, et al. Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. Leukemia Res 2004; 28: 249-57.","DOI":"10.1016\/S0145-2126(03)00259-5"},{"key":"ref-1169196","doi-asserted-by":"crossref","unstructured":"Camilleri M. Diagnosis and treatment of irritable bowel syndrome: a review. JAMA 2021; 325: 865-77.","DOI":"10.1001\/jama.2020.22532"},{"key":"ref-1169197","doi-asserted-by":"crossref","unstructured":"Horan RF, Sheffer AL, Austen KF. Cromolyn sodium in the management of systemic mastocytosis. J Allergy Clin Immunol 1990; 85: 852-5.","DOI":"10.1016\/0091-6749(90)90067-E"},{"key":"ref-1169198","doi-asserted-by":"crossref","unstructured":"Lee KN, Lee OY. The role of mast cells in irritable bowel syndrome. Gastroenterol Res Pract 2016; 2016: 2031480.","DOI":"10.1155\/2016\/2031480"},{"key":"ref-1169199","doi-asserted-by":"crossref","unstructured":"Singh A, Al-Kali A, Begna KH, et al. Midostaurin therapy for advanced systemic mastocytosis: Mayo Clinic experience in 33 consecutive cases. Am J Hematol 2022; 97: 630-7.","DOI":"10.1002\/ajh.26498"},{"key":"ref-1169200","doi-asserted-by":"crossref","unstructured":"Valent P, Akin C, Sperr WR, et al. Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol 2003; 122: 695-717.","DOI":"10.1046\/j.1365-2141.2003.04575.x"},{"key":"ref-1169201","doi-asserted-by":"crossref","unstructured":"Valent P, Akin C, Hartmann K, et al. Updated diagnostic criteria and classification of mast cell disorders: a consensus proposal. Hemasphere 2021; 5: e646.","DOI":"10.1097\/HS9.0000000000000646"},{"key":"ref-1169202","doi-asserted-by":"crossref","unstructured":"Zanelli M, Pizzi M, Sanguedolce F, et al. Gastrointestinal manifestations in systemic mastocytosis: The need of a multidisciplinary approach. Cancers 2021; 13: 3316.","DOI":"10.3390\/cancers13133316"},{"key":"ref-1169203","doi-asserted-by":"crossref","unstructured":"Reed CC, Genta RM, Youngblood BA, et al. Mast cell and eosinophil counts in gastric and duodenal biopsy specimens from patients with and without eosinophilic gastroenteritis. Clin Gastroenterol Hepatol 2021; 19: 2102-11.","DOI":"10.1016\/j.cgh.2020.08.013"},{"key":"ref-1169204","doi-asserted-by":"crossref","unstructured":"Mazreah SA, Shahsavari M, Kalati PA, et al. Immunohistochemical evaluation of CD117 in mast cell of aggressive periodontitis. J Indian Soc Periodontol 2020; 24: 216-20.","DOI":"10.4103\/jisp.jisp_243_19"},{"key":"ref-1169205","unstructured":"Scudamore CL, McMillan L, Thornton EM, et al. Mast cell heterogeneity in the gastrointestinal tract: variable expression of mouse mast cell protease-1 (mMCP-1) in intraepithelial mucosal mast cells in nematode-infected and normal BALB\/c mice. Am J Pathol 1997; 150: 1661."},{"key":"ref-1169206","doi-asserted-by":"crossref","unstructured":"Kristensen T, Vestergaard H, M\u00f8ller MB. Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay. J Mol Diagn 2011; 13: 180-8.","DOI":"10.1016\/j.jmoldx.2010.10.004"},{"key":"ref-1169207","doi-asserted-by":"crossref","unstructured":"Valent P, Akin C, Sperr WR, et al. New insights into the pathogenesis of mastocytosis: emerging concepts in diagnosis and therapy. Annu Rev Pathol 2023; 18: 361-86.","DOI":"10.1146\/annurev-pathmechdis-031521-042618"},{"key":"ref-1169208","doi-asserted-by":"crossref","unstructured":"Hatch EW, Geeze MB, Martin C, et al. Variability of PD-L1 expression in mastocytosis. Blood Adv 2018; 2: 189-99.","DOI":"10.1182\/bloodadvances.2017011551"},{"key":"ref-1169209","doi-asserted-by":"crossref","unstructured":"Kataoka TR, Fujimoto M, Moriyoshi K, et al. PD-1 regulates the growth of human mastocytosis cells. Allergol Int 2013; 62: 99-104.","DOI":"10.2332\/allergolint.12-OA-0450"},{"key":"ref-1169210","doi-asserted-by":"crossref","unstructured":"Pardanani A. Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management. Am J Hematol 2019; 94: 363-77.","DOI":"10.1002\/ajh.25371"},{"key":"ref-1169211","doi-asserted-by":"crossref","unstructured":"Williams M, Lidke DS, Hartmann K, et al. PD-L1 expression in mastocytosis. Int J Mol Sci 2019; 20: 2362.","DOI":"10.3390\/ijms20092362"},{"key":"ref-1169212","doi-asserted-by":"crossref","unstructured":"Akin C, Arock M, Valent P. Tyrosine kinase inhibitors for the treatment of indolent systemic mastocytosis: are we there yet? J Allergy Clin Immunol 2022; 149: 1912-8.","DOI":"10.1016\/j.jaci.2022.04.020"},{"key":"ref-1169213","doi-asserted-by":"crossref","unstructured":"Piris-Villaespesa M, Alvarez-Twose I. Systemic mastocytosis: following the tyrosine kinase inhibition roadmap. Front Pharmacol 2020; 11: 443.","DOI":"10.3389\/fphar.2020.00443"},{"key":"ref-1169214","doi-asserted-by":"crossref","unstructured":"Gotlib J, Reiter A, DeAngelo DJ. Avapritinib for advanced systemic mastocytosis. Blood 2022; 140: 1667-73.","DOI":"10.1182\/blood.2021014612"}],"container-title":["Archives of Medical Science"],"original-title":[],"link":[{"URL":"https:\/\/www.archivesofmedicalscience.com\/pdf-176943-114187","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.archivesofmedicalscience.com\/pdf-176943-114187","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T06:14:52Z","timestamp":1726726492000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.archivesofmedicalscience.com\/Diarrhea-predominant-irritable-bowel-syndrome-as-a-masquerade-for-systemic-mastocytosis,176943,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,25]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"alternative-id":["176943"],"URL":"https:\/\/doi.org\/10.5114\/aoms\/176943","relation":{},"ISSN":["1734-1922","1896-9151"],"issn-type":[{"type":"print","value":"1734-1922"},{"type":"electronic","value":"1896-9151"}],"subject":[],"published":{"date-parts":[[2024,4,25]]}}}